Trevor Allred
Stock Analyst at Oppenheimer
(4.92)
# 224
Out of 5,162 analysts
44
Total ratings
87.1%
Success rate
83.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $232 | $146.58 | +58.28% | 11 | Nov 20, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $78.01 | - | 10 | May 11, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $83.98 | - | 7 | May 11, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $18.40 | +90.22% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $250 → $275 | $298.71 | n/a | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Reiterated: Buy | $38 → $80 | $53.42 | n/a | 4 | Nov 7, 2025 |
Palvella Therapeutics
Nov 20, 2026
Reiterated: Buy
Price Target: $232
Current: $146.58
Upside: +58.28%
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $78.01
Upside: -
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $83.98
Upside: -
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $18.40
Upside: +90.22%
Ligand Pharmaceuticals
Nov 7, 2025
Reiterated: Buy
Price Target: $250 → $275
Current: $298.71
Upside: n/a
MBX Biosciences
Nov 7, 2025
Reiterated: Buy
Price Target: $38 → $80
Current: $53.42
Upside: n/a